Rifaximin: Difference between revisions
(Rifaximin page) |
(annotation) |
||
| Line 21: | Line 21: | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*No | *No adjustment | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*No adjustment | *No adjustment | ||
Revision as of 14:26, 20 January 2016
Administration
- Type: Antibiotic
- Dosage Forms: 200, 550
- Routes of Administration: Oral
- Common Trade Names: Xifaxan
Adult Dosing
- Traveler's diarrhea, E. coli-induced: 200 mg PO tid x3 days
- Hepatic encephalopathy: 550 mg PO bid
- IBS, diarrhea-predominant: 550 mg PO tid x14 days
- May repeat dose up to 2x if recurrent dz
Pediatric Dosing
For > 12 yrs old
- Traveler's diarrhea, E. coli-induced: 200 mg PO tid x3 days
Special Populations
Renal Dosing
- No adjustment
Hepatic Dosing
- No adjustment
Contraindications
- Allergy to class/drug
- caution if hepatic impairment (Child-Pugh Class C)
- caution if recent abx-associated colitis
Adverse Reactions
Serious
- superinfection
- C. difficile-assoc. diarrhea
- hypersensitivity rxn
- angioedema
- anaphylaxis
- exfoliative dermatitis
Common
- peripheral edema
- nausea
- dizziness
- fatigue
Comments
See Also
References
<Epocrates, UpToDate>